CAC
MLTX icon

Cowen and Company’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cowen and Company’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,173
Closed -$85K – 722
2022
Q2 		$85K Buy
+16,173
New +$102K 0.01% 260
2021
Q4 		– Sell
-62,475
Closed -$622K – 722
2021
Q3 		$622K Buy
+62,475
New +$623K 0.03% 176

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cowen and Company's MLTX Position: Q3 2022 in Review

Cowen and Company sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2022, closing a stake of 16,173 shares — an estimated $85K sold.

Cowen and Company first reported a position in MLTX in Q3 2021 and held it in 2 quarters. The position peaked at $622K in Q3 2021. 24 funds tracked by Wall St. Rank hold MLTX as of Q3 2022.

  • Cowen and Company reported no remaining MoonLake Immunotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 16,173 MoonLake Immunotherapeutics shares in Q3 2022, an estimated $85K.
  • Cowen and Company first reported a position in MoonLake Immunotherapeutics in Q3 2021 and held it in 2 quarters.
  • Cowen and Company's MoonLake Immunotherapeutics position peaked at $622K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.